PURPOSE: The World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF) is used for patients with schizophrenia although no validation is available. This work addresses this issue by dealing with its psychometric properties in a clinical sample of patients with schizophrenia. METHODS: Two hundred forty-one patients from 10 Adult Mental Health Care Centers (AMHCC) meeting the following inclusion criteria were included: (1) International Classification of Diseases-10 or ICD-10 diagnosis of schizophrenia, (2) Global Assessment of Functioning scores or GAF ≤ 50, 3) Illness duration of more than 2 years and (4) Clinical stability at assessment time. Patients were evaluated at baseline and at one-year follow-up regarding quality of life (QOL), clinical variables and other psychosocial measures. RESULTS: Internal consistency was excellent for the total WHOQOL-BREF (0.88 at baseline and 0.89 at follow-up) and adequate (0.65-0.78 at baseline; 0.66-0.79 at one-year follow-up) for the WHOQOL-BREF domains. Correlations between WHOQOL-BREF scores and those of global functioning, psychiatric symptoms, disability and social support ranged between small and large. There were significant differences between groups of patients with schizophrenia in the WHOQOL-BREF. Patients who were anxious, disabled, lacked social support and used more social services scored significantly lower in some or all WHOQOL-BREF domains. Changes in WHOQOL-BREF scores were positively associated with changes over time in global functioning, social support and use of health services, and negatively with psychiatric symptoms and disability (correlation coefficients between small and moderate). After one-year follow-up, patients improved in overall functioning and there was a decrease in psychiatric symptoms. CONCLUSIONS: This study shows that the WHOQOL-BREF has good reliability and validity, and suggests that it is suitable for the assessment of QOL in patients with schizophrenia.
PURPOSE: The World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF) is used for patients with schizophrenia although no validation is available. This work addresses this issue by dealing with its psychometric properties in a clinical sample of patients with schizophrenia. METHODS: Two hundred forty-one patients from 10 Adult Mental Health Care Centers (AMHCC) meeting the following inclusion criteria were included: (1) International Classification of Diseases-10 or ICD-10 diagnosis of schizophrenia, (2) Global Assessment of Functioning scores or GAF ≤ 50, 3) Illness duration of more than 2 years and (4) Clinical stability at assessment time. Patients were evaluated at baseline and at one-year follow-up regarding quality of life (QOL), clinical variables and other psychosocial measures. RESULTS: Internal consistency was excellent for the total WHOQOL-BREF (0.88 at baseline and 0.89 at follow-up) and adequate (0.65-0.78 at baseline; 0.66-0.79 at one-year follow-up) for the WHOQOL-BREF domains. Correlations between WHOQOL-BREF scores and those of global functioning, psychiatric symptoms, disability and social support ranged between small and large. There were significant differences between groups of patients with schizophrenia in the WHOQOL-BREF. Patients who were anxious, disabled, lacked social support and used more social services scored significantly lower in some or all WHOQOL-BREF domains. Changes in WHOQOL-BREF scores were positively associated with changes over time in global functioning, social support and use of health services, and negatively with psychiatric symptoms and disability (correlation coefficients between small and moderate). After one-year follow-up, patients improved in overall functioning and there was a decrease in psychiatric symptoms. CONCLUSIONS: This study shows that the WHOQOL-BREF has good reliability and validity, and suggests that it is suitable for the assessment of QOL in patients with schizophrenia.
Authors: P B Fitzgerald; C L Williams; N Corteling; S L Filia; K Brewer; A Adams; A R de Castella; T Rolfe; P Davey; J Kulkarni Journal: Acta Psychiatr Scand Date: 2001-05 Impact factor: 6.392
Authors: Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer Journal: BMC Psychiatry Date: 2018-06-28 Impact factor: 3.630
Authors: Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen Journal: Int J Methods Psychiatr Res Date: 2014-12-09 Impact factor: 4.035
Authors: Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey Journal: J Affect Disord Date: 2018-09-19 Impact factor: 4.839
Authors: Melissa J Rowthorn; D Rex Billington; Christian U Krägeloh; Jason Landon; Oleg N Medvedev Journal: Qual Life Res Date: 2019-08-10 Impact factor: 4.147
Authors: A G Nevarez-Flores; K Sanderson; M Breslin; V J Carr; V A Morgan; A L Neil Journal: Epidemiol Psychiatr Sci Date: 2018-10-01 Impact factor: 6.892
Authors: Ulrike Stentzel; Neeltje van den Berg; Kilson Moon; Lara N Schulze; Josephine Schulte; Jens M Langosch; Wolfgang Hoffmann; Hans J Grabe Journal: BMC Psychiatry Date: 2021-06-29 Impact factor: 3.630
Authors: Laia Mas-Expósito; Juan Antonio Amador-Campos; Juana Gómez-Benito; Lluís Mauri-Mas; Lluís Lalucat-Jo Journal: Community Ment Health J Date: 2014-06-28